Benitec Biopharma Inc BNTC 深 滬
已收盤 04-02 16:00:00 美东时间
10.92
-0.050
-0.46%
華盛通- 最 高11.02
- 今 開10.73
- 成交量 5.36万股
- 最 低 10.5701
- 昨 收 10.97
- 總市值 3.75亿
- 52周最高 17.15
- 市盈率 靜 --
- 換手率 0.16%
- 52周最低 9.85
- 委 比 31.15%
- 總股本 3435.43万
- 歷史最高 5609.5744
- 量 比 0.51
- 振 幅 4.10%
- 歷史最低 2.227
- 每 手 1
- 風險率 1.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma announced promising interim results from the BB-301 Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD) patients with moderate dysphagia. Both low and high doses of BB-301 showed significant improvements in throat closure, emptying, and dysphagic symptoms. High-dose BB-301 demonstrated particularly robust responses, with a 68% reduction in dysphagic symptom burden and improved outcomes across all assessments. Low-dos...
03-09 11:00
Benitec Biopharma BB-301 Phase 1b/2a Late-Breaking Abstract Accepted At 2026 Muscular Dystrophy Association Clinical And Scientific Conference
-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and
02-23 20:06
Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference
Benitec Biopharma Inc. announced that interim results from its Phase 1b/2a clinical trial of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) will be presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9. The presentation will include 12-month follow-up data for the first four Cohort 1 completers, 24-month results for the first Cohort 1 patient, and interim data for the first Cohort 2 patient. BB-301...
02-23 12:00
Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.
02-12 22:07
Benitec Biopharma Q2 net loss widens
Benitec Biopharma Q2 net loss widens Overview Gene therapy firm's Q2 net loss widened to $11.8 mln Company's R&D expenses in Q2 were $5.8 mln, consistent with last year Company plans FDA meeting mid-2026 for BB-301 pivotal study design Outlook Company plans FDA meeting to finalize BB-301 pivotal stu
02-12 21:37
Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response
Benitec Biopharma Inc. reported interim results from its BB-301 Phase 1b/2a study for OPMD-related dysphagia. Patient 1 showed durable disease-modifying effects at 24 months post-treatment, with significant improvements in pharyngeal residue and dysphagic symptoms. All four Cohort 1 patients demonstrated sustained response to BB-301 at 12 months, meeting predefined criteria. BB-301 uses a unique " Silence and Replace" mechanism targeting mutant P...
01-11 13:00
Benitec Biopharma Concludes 2025 Annual Stockholders Meeting
Benitec Biopharma ( ($BNTC) ) has shared an update. On December 1, 2025, Benite...
2025-12-03 06:48
Benitec Biopharma Inc. held annual stockholder meeting
Benitec Biopharma Inc. held its 2025 Annual Meeting of Stockholders on December 1, 2025. Stockholders elected Dr. Jerel Banks and Megan Boston to the board of directors. The appointment of the indepen...
2025-12-03 06:28
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
